Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay

ABHD16A is identified as a major enzyme catalyzing production of lyso-PS from phosphatidylserine (PS). A new ABHD16A inhibitor and knockout mice show a dynamic interplay occurring during inflammation between ABHD16A and disease-linked ABHD12, an enzyme that degrades lyso-PS. ABHD16A is identified as...

Full description

Saved in:
Bibliographic Details
Published inNature chemical biology Vol. 11; no. 2; pp. 164 - 171
Main Authors Kamat, Siddhesh S, Camara, Kaddy, Parsons, William H, Chen, Dong-Hui, Dix, Melissa M, Bird, Thomas D, Howell, Amy R, Cravatt, Benjamin F
Format Journal Article
LanguageEnglish
Published New York Nature Publishing Group US 01.02.2015
Nature Publishing Group
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABHD16A is identified as a major enzyme catalyzing production of lyso-PS from phosphatidylserine (PS). A new ABHD16A inhibitor and knockout mice show a dynamic interplay occurring during inflammation between ABHD16A and disease-linked ABHD12, an enzyme that degrades lyso-PS. ABHD16A is identified as a major enzyme catalyzing production of lyso-PS from phosphatidylserine (PS). A new ABHD16A inhibitor and knockout mice show a dynamic interplay occurring during inflammation between ABHD16A and disease-linked ABHD12, an enzyme that degrades lyso-PS. Lysophosphatidylserines (lyso-PSs) are a class of signaling lipids that regulate immunological and neurological processes. The metabolism of lyso-PSs remains poorly understood in vivo . Recently, we determined that ABHD12 is a major brain lyso-PS lipase, implicating lyso-PSs in the neurological disease polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC), which is caused by null mutations in the ABHD12 gene. Here, we couple activity-based profiling with pharmacological and genetic methods to annotate the poorly characterized enzyme ABHD16A as a phosphatidylserine (PS) lipase that generates lyso-PS in mammalian systems. We describe a small-molecule inhibitor of ABHD16A that depletes lyso-PSs from cells, including lymphoblasts derived from subjects with PHARC. In mouse macrophages, disruption of ABHD12 and ABHD16A respectively increases and decreases both lyso-PSs and lipopolysaccharide-induced cytokine production. Finally, Abhd16a −/− mice have decreased brain lyso-PSs, which runs counter to the elevation in lyso-PS in Abhd12 −/− mice. Our findings illuminate an ABHD16A-ABHD12 axis that dynamically regulates lyso-PS metabolism in vivo , designating these enzymes as potential targets for treating neuroimmunological disorders.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:1552-4450
1552-4469
1552-4469
DOI:10.1038/nchembio.1721